$12.31B in CY2024 Part D spend9.7M claims · 2.1M beneficiaries · 329 plans surveyed
Questions a plan sponsor actually asks.
What is Tirzepatide used for?
ZEPBOUND ® is indicated in combination with a reduced-calorie diet and increased physical activity: to reduce excess body weight and maintain weight reduction long term in adults with obesity or ad....
Is there a generic for Tirzepatide?
No. Tirzepatide is brand-only with no generic equivalents currently in market.
How much does my plan pay for Tirzepatide?
Across 329 Part D plans, Tirzepatide averages $532.43/unit (NADAC). Lowest available: $525.89/unit. Highest in distribution: $538.80/unit.
Is Tirzepatide on the FDA shortage list?
No. Tirzepatide is not currently on the FDA Drug Shortage Database.
7 additional drug-specific questions are indexed in the page's FAQPage schema for search engines and LLM crawlers, beyond what renders visually above. View page source for the complete JSON-LD.
Sources · every number above traces back.
Drug identity, dosage forms, brand names: openFDA NDC Directory · First approval, ANDA history: FDA Orange Book (10 approvals on file) · NADAC unit costs: CMS NADAC weekly file (12 NDCs benchmarked) · Formulary tier and PA placement: CMS Part D Formulary file (329 plans) · Annualized spend, claims, beneficiaries: CMS Part D Spending Dashboard (CY2024) · Shortage status: FDA Drug Shortage Database · 340B exposure: HRSA OPAIS. Methodology and reproducibility notes on /methodology.